Oncimmune Regulatory News (ONC)

1 March 2022

Oncimmune Holdings plc

("Oncimmune" or the "Company")

ImmunoINSIGHTS and Synexa Life Sciences sign go-to-market service partnership

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, is pleased to announce the signing of a go-to-market partnership with Synexa Life Sciences BV, a global leader in biomarker and bioanalytical science, focused on delivering a range of biomarker analytical and advisory services in translational and clinical research.

Following an assessment of ImmunoINSIGHT's competence and capability, Synexa Life Sciences has selected Oncimmune's ImmunoINSIGHTS platform to provide its clients access to specialist autoantibody services. This collaborative partnership will allow for comprehensive characterisation of the B-cell immune response in a wide range of disease and treatment indications.

Both companies utilise technologies to identify biological signatures, leveraging their deep expertise in the immunological underpinnings of health and disease to improve patient diagnostics and therapeutics. Over the next 18 months, Synexa Life Sciences plans to sign multiple new contracts with their partners for autoantibody profiling acting to broaden and enhance ImmunoINSIGHT's own business development efforts.

This new strategic collaboration comes at a time when autoantibody profiling, which provides a depth and breadth of clinical data to improve response and adverse event (irAE) prediction, patient screening and diagnostic accuracy, is experiencing substantial interest, with the market segment growing at approximately 27% year-upon-year.

Dr Adam M Hill, CEO of Oncimmune said: "We welcome this exciting initiative with Synexa Life Sciences, who have recognised the recent progress made by our ImmunoINSIGHTS platform. The ImmunoINSIGHTS team look forward to the opportunity to deliver high quality, value-adding analysis and interpretation of blood samples for Synexa and its clients, delivering a differentiated service to customers that are yet to engage with our proprietary technology platform."

For further information:

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk

Singer Capital Markets (Nominated Adviser and Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

+44 (0)20 7496 3000

WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Erland Sternby

+44 (0)20 3705 9321

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com

+44 (0)20 3727 1000

About Oncimmune

ImmunoINSIGHTS Service Business

Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. The ImmunoINSIGHTS service business leverages Oncimmune's technology platform and methodologies across multiple diseases, to offer life-science organisations actionable insights for therapies across the development and product lifecycle. Our core immune-profiling technology is underpinned by our library of over eight thousand immunogenic proteins, one of the largest of its kind. This helps identify trial participants and patients into clinically relevant subgroups, enabling development of targeted and more effective treatments.

Oncimmune's ImmunoINSIGHTS service business is based at the Company's discovery research centre in Dortmund, Germany. The business platform enables life science organisations to optimise drug development and delivery, leading to more effectively targeted and safer treatments for patients.

The ImmunoINSIGHTS development team is based in the US and Europe and Oncimmune is seeking to replicate the Dortmund facility in the US in the medium term.

EarlyCDT Product Business

Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market estimated to grow to £3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programmes, globally.

Oncimmune's diagnostic products business is located at its laboratory facility in Nottingham, UK.

For more information, visit www.oncimmune.com

About Synexa Life Sciences

For nearly 20 years, Synexa Life Sciences has supported their Biopharma partners across the globe to achieve their clinical milestones. Founded in 2003 as an early pioneer in the biomarker field, Synexa specializes in the development, validation and delivery of a wide range of complex and custom-designed assays, founded on deep expertise in immunology and the impact of the immune system on human health and candidate drug performance. For more information, please visit www.synexagroup.com

Synexa is a privately-held company, backed by Gilde Healthcare, a specialized European healthcare investor, and operates from three laboratory locations (London, Berlin and Cape Town).